GlassScriptPhysician profile
Jeffrey L Lew
NPI 1669853792
$868.51
in general payments reported to CMS, 2019-2025
23 companies · $358 in 2025
The $358 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $336 · 2021: $49.91 · 2024: $22.99 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $381.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $162.60 | 2019-2020 | |
| Karyopharm Therapeutics INC. | $69.01 | 2024-2025 | Xpovio |
| Genmab U.S., INC. | $65.53 | 2025 | Epkinly |
| Incyte Corporation | $56.59 | 2020-2025 | Jakafi, Niktimvo |
| Gilead Sciences, INC. | $51.76 | 2025 | Trodelvy |
| Exelixis INC. | $45.49 | 2019-2020 | |
| Tesaro, INC. | $42.33 | 2019 | |
| Glaxosmithkline, LLC. | $36.99 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $36.40 | 2020-2021 | |
| Abbvie INC. | $34.59 | 2025 | |
| Celgene Corporation | $30.07 | 2020-2021 | |
| Geron Corporation | $26.36 | 2025 | Rytelo |
| Sobi, INC | $26.04 | 2025 | |
| Fennec Pharmaceuticals, INC. | $24.68 | 2025 | Fyarro |
| Ipsen Biopharmaceuticals, INC | $22.50 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $22.02 | 2025 | Tevimbra |
| Genzyme Corporation | $21.61 | 2020 | |
| Aveo Pharmaceuticals, INC. | $19.43 | 2025 | |
| Puma Biotechnology, INC. | $18.97 | 2019 | |
| Amgen INC. | $14.67 | 2020 | |
| Lilly USA, LLC | $14.50 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $13.47 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Lew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.